Gene therapy for adenosine deaminase deficiency

Robertson Parkman, Kenneth Weinberg, Gay Crooks, Jan Nolta, Neena Kapoor, Donald Kohn

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (6) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.

Original languageEnglish (US)
Pages (from-to)33-47
Number of pages15
JournalAnnual Review of Medicine
Volume51
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Gene therapy
Adenosine Deaminase
Hematopoietic Stem Cells
Stem cells
Genetic Therapy
Genes
Inborn Genetic Diseases
T-cells
Fetal Blood
Severe combined immunodeficiency due to adenosine deaminase deficiency
Bone
Blood
Bone Marrow
T-Lymphocytes

Keywords

  • Gene expression
  • Gene therapy
  • Hematopoietic stem cell
  • Primary immunodeficiency
  • Retroviral vector

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

Parkman, R., Weinberg, K., Crooks, G., Nolta, J., Kapoor, N., & Kohn, D. (2000). Gene therapy for adenosine deaminase deficiency. Annual Review of Medicine, 51, 33-47. https://doi.org/10.1146/annurev.med.51.1.33

Gene therapy for adenosine deaminase deficiency. / Parkman, Robertson; Weinberg, Kenneth; Crooks, Gay; Nolta, Jan; Kapoor, Neena; Kohn, Donald.

In: Annual Review of Medicine, Vol. 51, 2000, p. 33-47.

Research output: Contribution to journalArticle

Parkman, R, Weinberg, K, Crooks, G, Nolta, J, Kapoor, N & Kohn, D 2000, 'Gene therapy for adenosine deaminase deficiency', Annual Review of Medicine, vol. 51, pp. 33-47. https://doi.org/10.1146/annurev.med.51.1.33
Parkman, Robertson ; Weinberg, Kenneth ; Crooks, Gay ; Nolta, Jan ; Kapoor, Neena ; Kohn, Donald. / Gene therapy for adenosine deaminase deficiency. In: Annual Review of Medicine. 2000 ; Vol. 51. pp. 33-47.
@article{2ea2398cded74c0b8b324d86cb8e5b38,
title = "Gene therapy for adenosine deaminase deficiency",
abstract = "The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (6) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.",
keywords = "Gene expression, Gene therapy, Hematopoietic stem cell, Primary immunodeficiency, Retroviral vector",
author = "Robertson Parkman and Kenneth Weinberg and Gay Crooks and Jan Nolta and Neena Kapoor and Donald Kohn",
year = "2000",
doi = "10.1146/annurev.med.51.1.33",
language = "English (US)",
volume = "51",
pages = "33--47",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Gene therapy for adenosine deaminase deficiency

AU - Parkman, Robertson

AU - Weinberg, Kenneth

AU - Crooks, Gay

AU - Nolta, Jan

AU - Kapoor, Neena

AU - Kohn, Donald

PY - 2000

Y1 - 2000

N2 - The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (6) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.

AB - The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (6) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.

KW - Gene expression

KW - Gene therapy

KW - Hematopoietic stem cell

KW - Primary immunodeficiency

KW - Retroviral vector

UR - http://www.scopus.com/inward/record.url?scp=0034093243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034093243&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.51.1.33

DO - 10.1146/annurev.med.51.1.33

M3 - Article

VL - 51

SP - 33

EP - 47

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -